Patents by Inventor Nancy S. Barta

Nancy S. Barta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prostaglandin E1 and E2 analogs for the treatment of various medical conditions
    Patent number: 8063240
    Abstract: A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: November 22, 2011
    Assignee: Cayman Chemical Company, Incorporated
    Inventors: Nancy S. Barta, Stephen D. Barrett, Gregory W. Endres, Andriy M. Kornilov, Kirk M. Maxey, Adam Uzieblo
  • Substituted morpholine compounds for the treatment of central nervous system disorders
    Patent number: 7659394
    Abstract: This invention relates to compounds of the formulae I wherein R1-R8, A, X, and Z are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: February 9, 2010
    Assignee: Pfizer Inc
    Inventors: Nancy S. Barta, Shelly Ann Glase, David L. Gray, Gregory A. Reichard, Lloyd Jerome Simons, Wenijan Xu
  • PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS
    Publication number: 20090221654
    Abstract: A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.
    Type: Application
    Filed: November 14, 2008
    Publication date: September 3, 2009
    Applicant: CAYMAN CHEMICAL COMPANY
    Inventors: Nancy S. Barta, Stephen D. Barrett, Gregory W. Endres, Andrei M. Kornilov, Kirk M. Maxey, Adam Uzieblo
  • PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS
    Publication number: 20090124695
    Abstract: A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.
    Type: Application
    Filed: November 14, 2008
    Publication date: May 14, 2009
    Applicant: CAYMAN CHEMICAL COMPANY
    Inventors: Nancy S. Barta, Gregory W. Endres, Andrei M. Kornilov, Kirk M. Maxey, Adam Uzieblo